Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Not yet recruiting · NCT06644495 · Registry updated 2024-10-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib | non-small cell lung carcinoma | Not yet recruiting | Not stated | 2024-10-16 | NCT06644495 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Qilu Pharmaceutical Co., Ltd. | 126 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||